Ozempic Gastroparesis Settlement: Understanding the Statute of Limitations in New Jersey

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specific Legal Concerns

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This broad legacy encompasses the communication of evolving pharmaceutical knowledge, including the mechanisms and intended benefits of widely prescribed medications. Within this tradition, the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic represented a significant advancement in managing metabolic disorders, with their use expanding rapidly across diverse patient populations. As clinical experience with these agents has grown, so too has the scope of inquiry into their full safety profile. A natural extension of this general health awareness is the focused examination of adverse events reported in association with long-term or high-dose exposure. Among these, the potential link between Ozempic and gastroparesis—a condition of delayed gastric emptying—has emerged as a subject of regulatory and legal scrutiny. This concern shifts the conversation from broad public health education to a more specific occupational and personal exposure context: individuals who have taken Ozempic and subsequently developed gastrointestinal symptoms consistent with gastroparesis may face complex decisions regarding their legal rights. In New Jersey, the statute of limitations for such claims imposes a strict time window for filing, making timely awareness of exposure history and legal recourse a critical matter for affected patients.

Find Out If You Qualify for Compensation →

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Among its known adverse effects, gastrointestinal reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis often involves gastric emptying scintigraphy. The mechanistic pathways linking Ozempic to gastroparesis are grounded in the pharmacology of GLP-1 receptor agonists. GLP-1 slows gastric emptying, which is part of its therapeutic effect on postprandial glucose. However, excessive or prolonged delay can lead to symptomatic gastroparesis. The reported gastrointestinal adverse reactions with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (placebo 0%, 0.5 mg 2.7%, 1 mg 1.1%), flatulence (placebo 0.8%, 0.5 mg 0.4%, 1 mg 1.5%), gastroesophageal reflux disease (placebo 0%, 0.5 mg 1.9%, 1 mg 1.5%), and gastritis (placebo 0.8%, 0.5 mg 0.8%, 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These adverse reactions, while not explicitly labeled as gastroparesis, reflect the spectrum of upper gastrointestinal dysfunction that can overlap with gastroparesis.

Adequacy of Warnings and Risk Communication

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not specifically list gastroparesis as a distinct adverse reaction. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may affect the adequacy of risk communication to patients and healthcare providers. For patients who develop gastroparesis after starting Ozempic, the timeline between exposure and documented harm is critical. Symptoms often emerge during dose escalation, as noted in clinical trials where the majority of nausea, vomiting, and diarrhea occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis may develop later, and the latency period can vary.

Statute of Limitations for Ozempic Claims in New Jersey

Settlement-related considerations for affected patients in New Jersey involve the statute of limitations, which governs the time frame within which a lawsuit must be filed. In New Jersey, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For gastroparesis allegedly caused by Ozempic, the clock may start when the patient is diagnosed or when symptoms become severe enough to prompt medical evaluation. Patients must also consider the timeline between exposure and documented harm. If a patient took Ozempic for several months before developing gastroparesis, the statute of limitations may begin at the time of diagnosis. However, if symptoms were present earlier but not recognized as related to the drug, the discovery rule may apply, extending the filing period. It is essential for patients to consult with a legal professional to assess their specific circumstances. In summary, the evidence indicates that Ozempic is associated with a higher incidence of gastrointestinal adverse reactions compared to placebo, and these reactions can include symptoms consistent with gastroparesis. The prescribing information does not specifically warn about gastroparesis, which may impact the adequacy of warnings. For New Jersey patients, the statute of limitations for filing a claim is typically two years from discovery of the injury, and the timeline between exposure and harm is a key factor in determining when that period begins. Patients should seek legal advice promptly to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in New Jersey?

In New Jersey, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Ozempic, is generally two years from the date the injury was discovered or should have been discovered. For gastroparesis allegedly caused by Ozempic, the clock may start when the patient is diagnosed or when symptoms become severe enough to prompt medical evaluation. The discovery rule may extend the filing period if symptoms were present but not recognized as related to the drug. It is crucial to consult with a legal professional promptly to preserve your rights.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is associated with a higher incidence of gastrointestinal adverse reactions compared to placebo, including nausea, vomiting, diarrhea, dyspepsia, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the prescribing information does not specifically list gastroparesis as a distinct adverse reaction, the symptoms and mechanisms (GLP-1 slows gastric emptying) overlap with gastroparesis. Clinical trials show that gastrointestinal reactions occur more frequently with Ozempic, and some patients may develop symptoms consistent with gastroparesis.

What should I do if I developed gastroparesis after taking Ozempic?

If you developed gastroparesis after taking Ozempic, you should seek medical evaluation for proper diagnosis and treatment. Additionally, consult with a legal professional experienced in pharmaceutical litigation to understand your rights and the applicable statute of limitations in New Jersey. Document your exposure history, including when you started and stopped taking Ozempic, and any symptoms or diagnoses. Prompt action is essential because the statute of limitations is generally two years from discovery of the injury.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.